ZMAT2

Across TCGA pan-cancer cohorts, ZMAT2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZMAT2 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZMAT2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZMAT2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where ZMAT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.808	0.349	.001	41	view →
HNSC	OS	Median	All	0.296	1.000	.003	33	view →
PDAC	DFS	Median	All	0.391	0.210	.002	28	view →
GBM	DFS	Quartile	All	0.491	0.242	.001	15	view →
LSCC	OS	Median	II,III,IV	1.000	0.885	.022	5	view →
CCRCC	OS	Quartile	All	0.568	1.000	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZMAT2–LUAD (OS)

Open the LUAD breakdown →